![]() ![]() NovoCodex Biopharmaceuticals China Private The company's innovative biologic drug anti-HER2 (product code: NCB001) is a new generation of monoclonal antibody conjugated drugs. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. Oncoternal USA Private Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. The company has relationships with Shanghai Cancer Institute and Shanghai Renji Hospital, plans to initiate clinical trials for KJgpc3-001, a glypican-3 (GPC3)-directed CAR-T cell therapy for liver cancer, and is advancing CAR-T therapies for lung and brain cancers in parallel. USA n/a Woomera Therapeutics is developing monoclonal antibody therapies to treat Breast, Lung and other forms of cancer using a unique understanding of vasopressin oncology biology.ĬARsgen China Listed CARsgen is a leading immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company, which is located in Lund, Sweden, is led by top-level scientists and biotech executives. Galecto Biotech’s high potency galectin modulators may open new treatment possibilities for many patients. ![]() ![]() The company’s products target galectins, a group of proteins that play important roles in many disorders. Galecto Biotech Denmark Listed Galecto Biotech was formed in December 2011 and is focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. ImmunoBiochem Corporation Canada n/a ImmunoBiochem is a secretome-focused biotech developing novel tumor microenvironment-targeted potentiated biologics designed to overcome cancer heterogeneity and poor penetration of biological therapeutics in solid tumors, like triple-negative breast cancer (TNBC). VentureRadar Research / Company WebsiteĪssociated sectors: monoclonal antibody TLR8 agonist ImmunoTAC technology Biopharmaceutical oncology virology fibrosis Biotech Cancer Biologics ![]() Enabled by the company's proprietary ImmunoTAC platform, Silverback's pipeline is rapidly advancing towards clinical studies in several therapeutic areas, including oncology and fibrosis. Silverback Therapeutics is a privately held biotechnology company advancing a pipeline of first-in-class therapies targeting fundamental disease pathways that are systemically delivered but locally active. Develops innovative, systemically delivered therapies targeting fundamental disease pathways, focusing on locally active treatments previously considered inaccessible. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |